Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson’s disease
- 5 May 2004
- journal article
- research article
- Published by Elsevier in Behavioural Brain Research
- Vol. 151 (1-2) , 303-312
- https://doi.org/10.1016/j.bbr.2003.09.007
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- The effects of PACAP and PACAP antagonist on the neurobehavioral development of newborn ratsBehavioural Brain Research, 2003
- Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activationThe FASEB Journal, 2003
- Modeling Parkinson's Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal PathwayExperimental Neurology, 2002
- Delayed Systemic Administration of PACAP38 Is Neuroprotective in Transient Middle Cerebral Artery Occlusion in the RatStroke, 2000
- Distribution of the mRNA for a pituitary adenylate cyclase-activating polypeptide receptor in the rat brain: An in situ hybridization studyJournal of Comparative Neurology, 1996
- Pituitary adenylate cyclase activating polypeptide (PACAP) potently enhances tyrosine hydroxylase (TH) expression in adrenal chromaffin cellsLife Sciences, 1994
- Pituitary adenylate cyclase activating polypeptide (PACAP) reduces food intake in micePeptides, 1992
- Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cellsBiochemical and Biophysical Research Communications, 1989
- Regional distribution of vasoactive intestinal peptide in brains from normal and parkinsonian subjectsPeptides, 1988
- Hypermotility induced by vasoactive intestinal peptide in the rat: Its reciprocal action to cholecystokinin octapeptidePeptides, 1985